Search | Clinical Trials Finder

Conditions: Overweight or Obesity
Interventions: TERN-601, Matching Placebo; Drug · Other
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more

Conditions: Genetic Forms of Extreme Obesity
Interventions: Not listed
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Overweight, Obesity
Interventions: COC, Maridebart Cafraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Obesity
Interventions: Liraglutide, Oral Semaglutide, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cypress, California

Conditions: Peripheral Artery Disease, Overweight or Obesity
Interventions: Weight loss, Exercise; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Nausea and Vomiting, Obesity
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • San Jose, California + 7 more

Conditions: Obesity, Overweight, or Chronic Weight Management
Interventions: aleniglipron or placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Phoenix, Arizona • Chicago, Illinois • Richfield, Minnesota + 8 more

Conditions: Antipsychotic-induced Weight Gain (AIWG)
Interventions: Miricorilant, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more

Conditions: Overweight and Obesity
Interventions: Apitegromab, Placebo, Tirzepatide; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more

Conditions: Obesity
Interventions: LIK066, Carbohydrate 50%, Carbohydrate 25%, Carbohydrate 8%, Carbohydrate 0%, Psyllium, Calcium carbonate; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Overweight or Obesity, Healthy
Interventions: Mixed berries, FOS, Control, Combination; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 20 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overweight or Obesity, Healthy
Interventions: LY4064912, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Los Alamitos, California • San Antonio, Texas

Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions: Tirzepatide; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 70
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more

Conditions: Diabetes, Hypertension, Pre-diabetes, Overweight, Obese, Weight, Adherence
Interventions: Stress Reduction& Healthy living; Other
Lead sponsor: Eco Fusion; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions: Mediterranean-based, carbohydrate restricted, calorie reduced diet; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Obesity, Overweight
Interventions: Oral semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Kissimmee, Florida + 10 more

Conditions: Obesity
Interventions: diet; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 4 Years to 9 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-1706, Placebo (NNC9204-1706); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Weight Loss
Interventions: VK2735, Placebo; Biological
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Pelham, Alabama • Los Angeles, California • Santa Ana, California + 17 more

Search by objective public record fields.

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Aleniglipron Phase 2 Body Composition Study

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Berries, Inflammation, and Gut Microbiome

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

Changing Eating Behaviors in Young Children: Should Healthy Foods be Increased or Unhealthy Foods Decreased?

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

VK2735 for Weight Management Phase 2

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities